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Abstract
Background: Facilitation of endogenous neuroprotective pathways, such as the erythropoietin
(Epo) pathway, has been proposed as adjuvant treatment strategies in cerebral malaria. Whether
different endogenous protein expression levels of Epo or differences in the abundance of its
receptor components could account for the extent of structural neuropathological changes or
neurological complications in adults with severe malaria was investigated.
Methods: High sensitivity immunohistochemistry was used to assess the frequency, distribution
and concordance of Epo and components of its homodimeric and heteromeric receptors, Epo
receptor and CD131, within the brainstem of adults who died of severe malaria. The following
relationships with Epo and its receptor components were also defined: (i) sequestration and
indicators of hypoxia; (ii) vascular damage in the form of plasma protein leakage and haemorrhage;
(iii) clinical complications and neuropathological features of severe malaria disease. Brainstems of
patients dying in the UK from unrelated non-infectious causes were examined for comparison.
Results:  The incidence of endogenous Epo in parenchymal brain cells did not greatly differ
between severe malaria and non-neurological UK controls at the time of death. However, EpoR
and CD131 labelling of neurons was greater in severe malaria compared with non-neurological
controls (P = .009). EpoR labelling of vessels was positively correlated with admission peripheral
parasite count (P = .01) and cerebral sequestration (P < .0001). There was a strong negative
correlation between arterial oxygen saturation and EpoR labelling of glia (P = .001). There were no
significant correlations with indicators of vascular damage, neuronal chromatolysis, axonal swelling
or vital organ failure.
Conclusion: Cells within the brainstem of severe malaria patients showed protein expression of
Epo and its receptor components. However, the incidence of endogeneous expression did not
reflect protection from vascular or neuronal injury, and/or clinical manifestations, such as coma.
These findings do not provide support for Epo as an adjuvant neuroprotective agent in adults with
severe malaria.
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Background
The ability of the brain to adapt to a range of insults may
be critical in determining whether patients are protected
from neurological complications and death during severe
malaria infection. Boosting endogenous protective mech-
anisms is a potential treatment strategy of current interest
in neurological diseases [1]. Erythropoietin (Epo) is a hae-
matopoietic growth factor produced primarily in the adult
kidney. Epo and its receptors are also expressed in tissue
outside the haematopoietic system and Epo has been
identified as a cytoprotective agent in both neuronal and
vascular systems. Administration of exogenous Epo is
neuroprotective in models of ischaemic and metabolic
stress but may aggravate neuronal damage when adminis-
tered during transient hypoxia [2]. Whether Epo is indif-
ferent, protects or damages the brain appears to be related
to the amount of Epo reaching the brain (reviewed in [3]).
Coma is a strong predictor of fatal outcome in severe
malaria across all age groups [4]. Neurological sequelae
are rarely observed in south-east Asian adults recovering
from cerebral malaria (CM), whereas a significant minor-
ity of African children suffer gross neurological sequelae
and a greater proportion have evidence of long-term neu-
rocognitive impairment (reviewed in [5]). High serum
levels of Epo have been associated with a reduced risk of
neurological sequelae in children with malaria in retro-
spective studies but cerebrospinal fluid (CSF) levels did
not reflect protection [6]. These data, together with results
from the Plasmodium berghei ANKA murine model have
focused attention on Epo as a potential neuroprotective
adjuvant therapy in CM [7-9]. Clinical trials of Epo are
underway in stroke and in African children with cerebral
malaria [10,11]
In this study, immunohistochemical techniques have
been used to investigate endogenous levels of Epo and
Epo receptor components in the medulla of the brainstem
of cases of fatal severe malaria in Vietnamese adults. The
brainstem was chosen for examination in this study as
severe malaria is often associated with brainstem signs.
The reticular activating system, involved in the mainte-
nance of consciousness, lies within the core of the pons
and medulla. Damage to the cardio-respiratory centres in
the medulla will lead to death.
There are few studies detailing the expression of Epo and
its receptors in non-tumour-related human brain disease
in adults [12-14] and using sensitive detection systems so
the first aim was to define the frequency and distribution
of expression in the medulla of severe malaria and non-
infectious deaths. Comparisons with control groups are
important to ensure differentiation of features specific to
malaria compared to background non-specific agonal
neuropathology. Hypoxia induces Epo and Epo receptor
expression [14-18]. Parasitized erythrocyte adherence to
cerebrovascular endothelial cells, a process termed
sequestration, causes microvascular obstruction. Com-
bined with other systemic complications of severe disease,
such as anaemia and shock, could cause hypoxic damage
to the brain in severe malaria (reviewed in [19]). It is,
therefore, important to define the relationship between
sequestration, the expression of Epo and its receptors and
indicators of hypoxia. Epo has been reported to inhibit
blood-brain barrier (BBB) permeability [20], so the rela-
tionship between Epo and its receptors and leakage of
plasma proteins into the brain parenchyma and frank vas-
cular damage in the form of haemorrhage was also inves-
tigated.
Neurological complications reflect neuronal dysfunction
and Epo and its derivatives have been shown to provide
histological evidence of neuronal protection and clinical
improvement in a range of animal models [21-23]. The
relationship was investigated between endogenous Epo
and its receptors, and potentially reversible neuronal
injury in the form of chromatolysis [24] and axonal injury
that are characteristic features of CM in southeast Asian
adults [25,26]. Epo is primarily produced by the kidney
and is induced in response to anaemia, so the impact of
other systemic complications of malaria disease, includ-
ing renal failure and anaemia, on Epo expression in the
brain was investigated. Finally, although neuroprotective
Epo signalling is not fully understood it has been hypoth-
esized to occur through two receptors: a high affinity,
homodimeric (EpoR/EpoR), and a low-affinity, hetero-
meric (CD131/EpoR) receptor (reviewed in [27]). CD131,
also known as the common beta receptor, is a signal trans-
ducing subunit shared by the granulocyte-macrophage
colony stimulating factor, and the interleukin (IL)-3 and
IL-5 receptors [3,28]). The concordance and relative abun-
dance of EpoR and CD131 in serial sections of medulla of
the brainstem was determined and the relationship with
structural brain changes was investigated.
Methods
Case selection
Autopsy brain specimens were taken within 24 hours of
death from adult patients who had died of severe falci-
parum malaria on the Malaria Ward, Centre for Tropical
Diseases, Ho Chi Minh City, Vietnam, as described previ-
ously [29]. These patients were divided into two groups:
CM (n = 10) and non-CM (n = 10). CM was defined
according to World Health Organization guidelines on
the basis of a Glasgow coma score of 11 or less [30], other
causes of unconsciousness having been excluded (e.g.
hypoglycaemia, meningitis or other encephalopathy), by
clinical, biochemical and CSF examination. Non-CM
patients were those dying from severe malaria without
coma, who had a range of clinical features typical of otherMalaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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vital organ system complications (see Table 1 for more
details).
Control cases (n = 12) were from different causes of death
in patients undergoing autopsies at the John Radcliffe
Hospital, Oxford, UK [31]. Autopsy delays varied but were
predominantly conducted within 24-48 hours of death.
These cases were divided into neurological and non-neu-
rological deaths (see Table 2). Protocols for tissue sam-
pling, storage and use were approved by the Ethical and
Scientific Committee of the Centre for Tropical Diseases,
Vietnam, OXTREC 029-02, COREC (C01.002) and the
Human tissue authority license number 12217.
Immunohistochemistry
Immunolabelling was assessed either using a semi-quan-
titative scale evaluated at the microscope by two inde-
pendent observers or by semi-automated, quantitative
image analysis. Epo, EpoR and CD131 were preferentially
assessed by eye using the semi-quantitative scale to allow
the distinction of labelling phenotype by a range of differ-
ent cell types and vessels of different sizes. The image anal-
ysis method evaluates the total amount of
immunostaining over the section and is therefore more
suitable for markers that give a diffuse staining pattern
and are difficult to give a subjective score, such as fibrino-
gen.
Brain samples were collected at autopsy, preserved in 10%
formalin for approximately six weeks, embedded in paraf-
fin and sectioned on a microtome just prior to immunos-
taining. Control brain samples were acquired at a similar
time period and paraffin tissue blocks were exposed to
identical storage conditions as the malaria cases in the
NDCLS, Oxford. Immunohistochemistry was performed
on 5 μm paraffin-embedded tissue sections of medulla
using the following antibodies or antisera: Epo (polyclo-
nal, Abcam, Cambridge 1:65), CD131 (rabbit mono-
clonal, Abcam, 1:100), EpoR (monoclonal anti-human,
R&D Systems Europe, Abingdon) and fibrinogen (rabbit
antisera, DAKO, Ely). Paraffin sections were dewaxed,
rehydrated and then underwent microwave antigen
retrieval or proteinase K digestion (for fibrinogen only: 5
min, room temperature, DAKO, S3020).
Bound antibody was visualized using the EnVision HRP
kit, Catalysed signal amplification kit (DAKO) or the
Novolink Polymer detection system (Leica Biosystems
Newcastle Ltd, UK). Positive controls in addition to fatal
neurological deaths from the UK (Table 2) included sec-
tions of lymphoma as indicated by the antibody manufac-
turer. Negative controls comprised sections
immunostained as above apart from omission of the pri-
mary antibody or replacing the primary antibody with an
isotype control.
Semi-quantitative scoring of immunostaining
The degree of Epo, EpoR or CD131 immunolabelling
associated with vessels (small and large), glia and neurons
was semi-quantitated using the following scale: no stain-
Table 1: Malaria patient data
Patient no Drug Age (yrs) Sex Time to death (h) GCS
Admission → Death
Convulsions CSF  opening 
pressure (mmHg)
Additional Clinical 
History
CM1 Q 36 F 52 6 → 3 No High (20) J, A, ARF, HG, S
CM2 A 22 M 38.5 7 → 3 No Normal (9.5) J, HP, HG, S
CM3 A 69 M 336 8 → 3 No ND J, A, ARF, HG, S
CM4 Q 34 M 6.6 8 → 3 No Normal (10) J, A, ARF, PO, HG, S
CM5 Q 36 M 20.66 8 → 3 Yes High (23) HP, J, ARF, HG, S
CM6 Q 30 M 36 7 → 3 No Normal (17) J, A, ARF, PO, S
CM7 Q 29 M 9 6 → 3 No High (24) PO, S
CM8 Q 63 M 16 10 → 3 No Normal (9) A, HG, PO, S
CM9 Q 44 M 39 7 → 3 No High (21) J, ARF, HG
CM10 A 44 F 24 7 → 3 Yes Normal (17) A, S
NCM1 Q 22 M 6.33 14 → 3 No ND J, HP, PO, S
NCM2 Q 63 M 50 11 → 3 No High (21.5) J, A, ARF, PO, S
NCM3 Q 43 F 94.5 15 → 3 No ND HP, J, A, ARF, HG, S
NCM4 Q 25 M 124 15 → 3N o N D J ,  A ,  H G
NCM5 Q 22 M 6 11 → 3 No Normal (14) HP, J, A, ARF, S
NCM6 Q 22 F 27.3 12 → 3 No ND HP, J, ARF, HG, S
NCM7 Q 54 M 35 11 → 3 Yes Normal (13.5) J, A, ARF, S
NCM8 A 56 F 4.66 13 → 3 No ND J, ARF, S
NCM9 Q 24 M 113 14 → 3 No ND J, A, S
NCM10 A 50 F 264 15 → 3 No High (19) J, A, ARF, S
Abbreviations: Q, quinine; A, artemether; CM, cerebral malaria; NCM, non-cerebral severe malaria; J, jaundice; A, anaemia; ARF, acute renal failure; 
HP, hyperparasitaemia; HG, hypoglycaemia, ND, not determined; S, haemodynamic shock, PO, pulmonary oedema.Malaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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ing/grade 0, <1% cells or vessels staining/grade 1, 1 - 10%
cells or vessels staining/grade 2, >10% cells or vessels
staining/grade 3. The relative abundance of CD131 to
EpoR was determined: 0, no staining for either CD131 or
EpoR; 1, grade of immunolabelling for CD131 < EpoR; 2,
grade of immunolabelling for CD131 = EpoR; 3, grade of
immunolabelling for CD131 > EpoR.
Histopathological correlation
Epo, EpoR and CD131 were visualized using exception-
ally high sensitivity detection systems (Leica Microsys-
tems, DAKO) that preclude the possibility of double
labelling procedures on the same tissue sections. Identifi-
cation of the cellular expression of these markers was
based on nuclear morphological and dimensional charac-
teristics as well as location within the gray and white mat-
ter of the medulla. Neurons were identified in the gray
matter by their large nuclei and prominent nucleolus as
well as pigment granules, Nissl's substance or lipofuscin
within the cytoplasm. Glia can be subdivided into astro-
cytes, microglia, oligodendrocytes and ependymal cells
but no attempt was made to distinguish between sub-
types for this study. Glia were distinguished from neurons
by nuclear phenotype. In general, glial nuclei are smaller,
lack nucleoli but often contain clumps of heterochroma-
tin and frequently are found in a satellite position. Blood
vessels were identified by their narrow tubular profiles.
Layers of the vessel walls can be clearly identified using
counterstains with endothelial cells providing the inner
most layer and smooth muscle cells, pericytes and perivas-
cular macrophages in the surrounding layers.
Concordant or discordant expression of Epo, EpoR and
CD131 were assessed by performing immunolabelling on
serial sections. Since our semi-quantitative scoring system
is based on the number (or incidence) of cells staining
rather than the intensity of staining then concordant
expression would only occur in serial sections with iden-
tical scores (although the reverse is not necessarily true).
Quantitation of fibrinogen using digital image analysis
Fibrinogen immunolabelling was quantified using a mod-
ified version of a semi-automated method previously used
for β-amyloid precursor protein in tissue sections from
severe malaria cases [26]. Briefly, tissue sections were dig-
itized using the EverSmart Pro II flat bed scanner (CreoSci-
tex, Canada). Regions of low, medium and high levels of
immunolabelling were selected by density thresholding of
grey scale converted images using SigmaScan Pro5 image
analysis software (SYSTAT, San Jose, CA). Thresholds were
selected by comparison of the staining intensity on non-
neurological and neurological UK control sections as
guides for setting the computerized low and high thresh-
olds respectively. These were kept constant between cases.
The total area of the tissue sections was calculated. The
amount of fibrinogen load was expressed as the area of tis-
sue covered by staining divided by the total area of the sec-
tion in square μm.
Clinicopathological correlation
Correlations of immunohistochemical staining patterns
for the various markers were conducted with clinical com-
plications of severe malaria including: anaemia (haemat-
ocrit < 20% plus parasitaemia > 100 000 μl),
haemodynamic shock (systolic blood pressure < 80
mmHg), pulmonary oedema, hypoglycaemia (plasma
glucose < 2.2 mmol/L), admission peripheral parasitae-
mia, jaundice (bilirubin >2.5 mg/dL), hyperlactataemia
(plasma lactate>5 mmol/L) and acute renal failure
(plasma creatinine >3 mg/dL). All clinical and biochemi-
Table 2: Control Patient data
Patient  Age (y) Sex Neurological history Additional Clinical History/Cause of death
C1 30 M N/A Congenital myelodysplasic syndrome; abscess.
C2 56 F Stupor due to depression/schizophrenia Dehydration; bronchopneumonia.
C3 35 M N/A Extensive severe burns of the skin; smoke inhalation.
C4 35 M Epilepsy; previous encephalitis. Pulmonary oedema
C5 27 M Unconscious; right-sided focal fit. Pulmonary oedema; hypoglycaemia.
C6 23 F N/A Sickle cell trait; severe haemorrhage.
C7 45 M N/A Pulmonary oedema; splenomegaly.
C8 39 F N/A Chronic renal failure; gastric bleed.
C9 43 F Ischaemic brain injury from hypovolaemic C-R 
arrest.
Renal transplant; CMV hepatitis; C-R arrest.
C10 78 F Confusion; hyperosmolar non-ketotic diabetic 
coma.
Rheumatoid arthritis; anaemia; heart failure; non-insulin-dependent 
diabetes mellitis; bronchopneumonia.
C11 73 M Infarction with cerebral atrophy; impaired 
cerebral function; coma.
Mitral valve replacement; cardiac failure; renal failure.
C12 86 M Infarction; brain atrophic; perivascular oedema. Bilateral bronchopneumonia and pleural fibrosis; myocardial 
infarction.
Abbreviations: N/A, not applicable. No history of neurological signs or symptoms; C-R, cardiorespiratory; CMV, cytomegalovirus. C1-C8, Brains 
showed no structural histological abnormality on standard neuropathological examination.Malaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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cal analyses were performed as part of the patients' clinical
work-up during their stay in hospital. No analyses were
performed on long-term, frozen archival plasma/CSF
samples. Retrospective analysis of Epo protein in archival
CSF samples from these patients was not performed since
growth factors such as Epo only survive in frozen CSF for
less than three months [32].
Statistics
Data were analysed using non-parametric tests where
appropriate (Kruskal-Wallis test, Spearman rank correla-
tion, and Fisher's exact test) using SPSS 13 (Chicago,
USA). No adjustments for multiple comparisons were
made, although, for the purposes of interpretation and
discussion, P < .01 was regarded as significant.
Results
Frequency and distribution of Epo, EpoR and CD131 
immunolabelling
Few studies have analysed Epo, EpoR or CD131 on paraf-
fin-embedded human brain tissue so each primary anti-
body was tested with several visualization systems.
Optimal staining could only be obtained using exception-
ally high sensitivity, polymer technology or catalysed sig-
nal amplification systems that are reported to have up to
50-fold greater sensitivity compared with traditional
(strept)avidin-biotin complexes (DAKO). The down side
of improved sensitivity was the preclusion of labelling
multiple proteins on the same tissue section. Epo and
EpoR were visualized using the Novolink Polymer detec-
tion system (Leica Biosystems Newcastle Ltd, UK) and
CD131 was only detectable using the catalysed signal
amplification kit (CSA, DAKO). It is unlikely that the low
CD131 signal reflects degradation of the antigen in the
malaria sections since the CSA kit was also required for
optimal staining of the lymphoma positive control sec-
tions. Weak avidity of the antibody or low level protein
expression in brain are in keeping with a recent study of
CD131 in rat brain [33]. No differences were observed
between the frequency of Epo or EpoR labelled cells visu-
alized with the Novolink or CSA kit but high diffuse back-
ground noise was less frequently observed with Novolink
for these antibodies.
Epo
Epo protein was expressed strongly in the cytoplasm and
or nucleus of a range of cells in the severe malaria and
control groups (Figures 1 &2A-B). The most striking stain-
ing was seen in neuronal cell bodies across all groups (Fig-
ures 1A-B &2A). Epo labelling of axons was only observed
in one CM case and was not observed in non-CM sections.
Epo labelling of glia was not a consistent feature of severe
malaria (Figure 1C, arrows) but strong immunolabelling
was found in the UK neurological control group (Figure
2B). The frequency of Epo labelling of glia was signifi-
cantly lower in severe malaria cases compared with the
neurological controls (P = .004). Endothelial labelling for
Epo could be observed in 30% (6/20) of brainstem sec-
tions from severe malaria cases (Figure 1C-E), but could
not be identified in the neurological controls. Intravascu-
lar serum staining for Epo was found in 75% (15/20) of
severe malaria and 100% (4/4) of UK neurological con-
trol cases (Figure 1A, arrow) which would obscure posi-
tive endothelial labelling. Epo was also observed on
pericytes/smooth muscle cells (Figure 1C-D) confirmed
by smooth muscle actin immunostaining (data not
shown).
EpoR
In general, there was a greater frequency of cytoplasmic
and/or nuclear EpoR labelling of cells within the brain-
stem sections compared with Epo (Figures 2A-D &3). The
frequency of EpoR in neuronal cell bodies of severe
malaria cases (Figure 3A-C) was greater than in non-neu-
rological controls (P = .009, Figure 2C). EpoR labelling of
axons was only observed in one CM section and was not
observed in non-CM. There was a greater incidence of
EpoR in neurons in the non-CM group compared with the
CM group (P = .01). However, this was not the case for
glia. Neurological controls showed consistently high lev-
els of glial labelling for EpoR whereas the severe malaria
and non-neurological controls showed a heterogeneous
incidence of staining within each group (Figure 2D).
EpoR immunolabelling was associated with vessels of var-
ying calibre in 80% (16/20) of the severe malaria brain-
stem sections (Figure 3D-H). Labelling was associated
with endothelial cells, pericytes/smooth muscle cells,
perivascular glia (Figure 3H) of the BBB as well as intra-
vascular monocytes. Of these cases, 35% (7/20) showed
labelling of endothelial cells. There was no statistical dif-
ference between the frequency of EpoR labelling between
vessels or endothelial cells and the different patient
groups (P > .42).
CD131
CD131 showed staining of the same cellular elements as
EpoR (Figure 1F-G). There was a greater frequency of
labelling of neuronal cell bodies in severe malaria com-
pared with non-neurological controls (P = .009, Figure
2E). CD131 labelling of axons was observed in sections
from two non-CM cases. In line with the findings for
EpoR, CD131 levels on glia were heterogeneous across all
patient groups (Figure 2F). CD131 was found on the same
vascular elements of small and larger vessels in severe
malaria sections as EpoR, but the incidence was much
lower (CD131: 30% (6/20) versus EpoR: 80% (16/20)).
CD131 labelling of endothelial cells was observed in 25%
(5/20) of cases (Figure 1F).Malaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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Double labelling for both EpoR and CD131 was not pos-
sible in this study so concordance of the incidence of
marker expression was examined in serial sections.
Although CD131 showed staining of the same cell subsets
as EpoR concordance was not always observed. The
strongest concordance occurred with neurons where 60%
(12/20) of the severe malaria cases showed the same
regional staining pattern and incidence of staining which
was a score of 3 for both markers. Glial staining of EpoR
and CD131 was heterogeneous across cases and discord-
Figure 1
Characteristic staining patterns for Epo and CD131 in the medulla of the brainstem. A. Strong intravascular
serum staining for erythropoietin (Epo, arrow). A range of staining intensities for Epo in the cytoplasm of neu-
rons. B. Immunostaining for Epo in the nucleus and cytoplasm of neurons. Neurons and small vessels without
Epo staining can be observed in this field. C. Two adjacent vessel showing strong endothelial and lighter peri-
cyte/smooth muscle cell labelling for Epo. Glial cells with Epo labelling of processes are also shown (arrows). D.
High power image of a pial vessel showing endothelial and pericyte/smooth muscle labelling. E. High power
image of a parenchymal vessel with sequestered malaria parasites and Epo labelling of endothelial cells. F.
Immunolabelling for CD131 on large and small (see insert) vessels. Labelling is found on both endothelial cells
and pericytes/smooth muscle cells. The large vessel shows perivascular haemorrhage and oedema. G. Neurons
from a control case with ischaemia showing immunolabelling for CD131. Staining is cytoplasmic with enhance-
ment at the plasma membrane (see insert). Scale bars: A-C, F, G, 50 μm; D, 25 μm; E, 10 μm.Malaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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ant in incidence and location in serial sections with only
15% (3/20) of severe malaria cases showing a similar inci-
dence of both markers and one case showing no staining
for either marker. Vessels showed a predominance of
EpoR labelling (see above), only 20% (4/20) of severe
malaria cases showed the same incidence of both markers
and 20% (4/20) of cases showed no staining for either
marker. The relative abundance of EpoR to CD131 is
described in section 6ii and Figure 2G-H.
Relationship between Epo, EpoR and CD131 
immunostaining, parasite load and cerebral sequestration
Among the severe malaria cases the mean admission
peripheral parasite count was 270 500 per mm3 (95% CI
(lower bound - upper bound): 130 800 - 410 100). At the
time of death the mean parasite load (% vessels seques-
tered) in the brainstem was 31.42% (95% CI: 13.71 -
49.13). There was a positive correlation between the fre-
quency of EpoR on vessels (including endothelial cells,
pericytes/smooth muscle cells and glial endfeet; see Figure
3) and admission parasite count (P = .01, r = .56). The
median sequestration levels observed on sections with
Epo, EpoR or CD131 immunolabelling on endothelial
cells was greater than sections without marker labelling
but this was not statistically significant (Epo: 5.00 [3.64-
46.51] versus 53.0 [8.79-89.60]; EpoR: 4.00 [2.69-41.61]
versus 57.5 [8.71-94.29]; CD131: 6.00 [9.30-48.30] ver-
sus 33.5 [0-115.01]; Median [95%CI]).
There was a strong correlation between the grade of EpoR
associated with vessels and sequestration levels in the
brainstem (P < .0001, r = .72). Sections with low seques-
tration load (<50% vessel sequestration) did not show
any staining for CD131 on pericytes/smooth muscle cells
but 43% (3/7) of sections with high sequestration showed
CD131 in this cell type (P = .04). No staining of Epo or its
receptors was seen in sequestered parasitized erythrocytes.
Relationship between Epo, EpoR and CD131 
immunostaining and vascular permeability and 
haemorrhage
There was heterogeneity in the amount of fibrinogen leak-
age in the brainstem of patients with severe malaria and
controls (see Table 3). In general, median levels of fibrin-
ogen leakage for the non-neurological control group were
less than the severe malaria group and the median levels
of fibrinogen leakage in the neurological UK controls
were greater than the severe malaria group. However, due
to the heterogeneity within groups this was not statisti-
cally significant. There were no statistically significant cor-
relations between Epo, EpoR or CD131 and fibrinogen
leakage. Haemorrhage, a consequence of frank vessel rup-
ture, was semi-quantitated in the brainstem sections (see
Table 4, [25]). There was a trend for a greater incidence of
haemorrhage in sections without EpoR in glia compared
with sections with EpoR in glia (P = .04).
Relationship between Epo, EpoR and CD131 
immunostaining and organ failure
Clinicopathological correlations were performed for the
frequency of Epo, EpoR and CD131 immunolabelling
and jaundice, anaemia, acute renal failure, hypoglycae-
mia, pulmonary oedema and haemodynamic shock.
Cases with acute renal failure had a lower frequency of
EpoR labelling of glia in the brainstem (P = .02). There
were no statistically significant correlations.
Relationship between Epo, EpoR and CD131 
immunostaining and indicators of hypoxia
Among the severe malaria cases, the plasma and CSF lac-
tate levels (6.1 ± 2.16 mmol/L and 6.4 ± 2.46 mmol/L,
median ± SD, respectively) and plasma and CSF lactate
pyruvate ratios (192.35 ± 187.15 and 42 ± 18.03, respec-
tively) were greater than levels reported for normal adults
(normal values: plasma lactate, 0.97 mmol/L; CSF lactate,
1.1-2.2 mmol/L; lactate pyruvate ratio 20:1 in normal bio-
logical fluids [34]). Arterial oxygen saturation was meas-
ured on admission using pulse oximetry. Median arterial
oxygen saturation was 97% (range: 90.8 - 99.2%).
There was a strong negative correlation between arterial
oxygen saturation measured on admission and EpoR
labelling of glia (P = .001, r = -.82). Median admission
arterial oxygen saturation was lower in sections with EpoR
labelling of smooth muscle/pericytes (P = .01). There was
no correlation between admission plasma lactate levels or
the plasma or CSF lactate pyruvate ratio and the frequency
of Epo, EpoR and CD131 immunostaining on neurons.
There was a trend toward a positive correlation between
CSF lactate levels and the frequency of Epo labelling of
glia (P = .04, r = .58).
Relationship between Epo, EpoR, CD131 and 
neuroprotection
(i) Axonal injury, astrogliosis and neuronal chromatolysis
A semi-quantitative assessment of swollen axons and
astrogliosis and quantitation of the number of centres
with chromatolytic neurons in the brainstem from forma-
lin-fixed paraffin embedded sections from the same
patients had been determined in a previous study [25].
Transverse sections were analysed between the midbrain
and the pontomedulllary junction, stained with haema-
toxylin and eosin, solochrome-cyanin, and periodic acid-
Schiff. A summary of the findings is shown in Table 4.
There were no correlations between the frequency of Epo,
EpoR or CD131 labelling in the medulla and the neu-
ropathological features in the brainstem of the same cases
with the exception of Epo labelling of neurons and astro-
gliosis (r = .85, P < .0001).Malaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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Frequency of immunoreactivity for Epo, EpoR and CD131 on neurons and glia Figure 2
Frequency of immunoreactivity for Epo, EpoR and CD131 on neurons and glia. A-F. The degree of staining per tis-
sue section with the various markers was semi-quantitated using the following grading scale: 0, no staining; 1, <1% cells staining; 
2, 1%-10% of cells staining; 3, >10% cells staining. G-H. The relative abundance (r.a.) of CD131 to EpoR was determined for 
each brainstem section: 0, no staining for either CD131 or EpoR; 1, grade of immunolabelling for CD131 < EpoR; 2, grade of 
immunolabelling for CD131 = EpoR; 3, grade of immunolabelling for CD131 > EpoR. Each dot represents the results from a 
brainstem section of an individual patient. Results are divided into patient groups: NNC, non-neurological UK control; non-
CM, non- cerebral malaria; CM, cerebral malaria; NC, neurological UK control (see Tables 1 & 2 for detailed patient descrip-
tions).Malaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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Characteristic staining patterns for Epo receptor in the medulla of the brainstem Figure 3
Characteristic staining patterns for Epo receptor in the medulla of the brainstem. A-C. Neurons staining for the 
erythropoietin receptor (EpoR). A. Cytoplasmic staining of neurons and perinuclear enhancement (white arrow). Nuclear and 
perinuclear staining of glia (filled arrow) and immunostaining of a small vessel (arrow head) can also be observed in this field. B. 
Cytoplasmic and strong perinuclear staining for EpoR in a neuron (white arrow) and cytoplasmic staining of microglia for EpoR 
(filled arrow). C. Nuclear staining for EpoR in a neuron. There is no cytoplasmic staining of neurons or vessels in this field. D. 
A small and medium sized vessel showing strong EpoR staining. E-G. Large vessels showing different patterns of EpoR immu-
nolabelling. E. EpoR staining on the outer vessel structures and no staining on endothelial cells. F. Light EpoR staining associ-
ated with a vessel showing intravascular parasite burden. G. EpoR staining on endothelial cells and pericytes/smooth muscle 
cells. This image also shows nuclear staining in glia (filled arrow). H. A small vessel with intravascular parasites showing perivas-
cular glial immunolabelling for EpoR (filled arrow). A perineuronal glia (white arrow) and a cluster of glia (arrow head) showing 
immunolabelling for EpoR. Scale bars: A, D, H, 25 μm; B-C, 25 μm; E-F, 50 μm.
Table 3: Fibrinogen leakage in the brainstem of severe malaria cases and UK controls
Fibrinogen Leakage Non-neurological UK controls Non-CM Cerebral malaria Neurological controls
High 13.29 [8.05-26.12] 32.22 [15.09-54.50] 18.97 [9.32-47.32] 54.39 [5.70-91.53]
Medium 18.27 [10.48-25.75] 21.47 [12.83-29.89] 22.60 [14.61-27.65] 16.19 [9.49-25.45]
Low 68.91 [48.83-80.77] 39.82 [23.82-63.87] 50.53 [30.48-70.61] 25.69 [0-74.57]
Geometric mean of fibrinogen load (%tissue section area) [95% confidence intervals]Malaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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(ii) Relative abundance of CD131 to EpoR
In severe malaria, there was a greater relative abundance
of CD131 compared to EpoR on neurons in CM patients
compared with non-CM cases (P = .005; Figure 2G). There
were no statistical correlations with glia, endothelial cells
or vessels.
Discussion
The aims of this study were to define the endogenous
expression of Epo and its receptors in the brainstem of
cases of fatal severe malaria and identify potential sys-
temic and local regulatory factors. Whether different
expression levels or differences in the abundance of recep-
tor components could account for the extent of structural
neuropathological changes was also investigated. The ulti-
mate aim was to provide a scientific-based rationale for or
against the use of Epo as a neuroprotective adjuvant treat-
ment strategy in adults with severe malaria.
The frequency of cell-associated Epo labelling in the
brainstem of severe malaria cases was not strikingly differ-
ent from non-infectious, non-neurological fatal cases
from the UK. However, Epo receptor labelling of neurons
was more frequent in severe malaria compared with the
non-neurological controls. Epo produced within the brain
and systemically produced soluble Epo that accessed the
brain could not be distinguished in this study. Recom-
binant human Epo (rhEpo) delivered systemically in rats
is found associated with cerebral capillaries when exam-
ined 5 h later. At 17 h, pericapillary Epo is absent and,
instead, localized to scattered neurons [35]. Epo in serum
was observed in 75% of the severe malaria brainstem sec-
tions and would have had access to the brain either via a
receptor-mediated transport mechanism in the cerebral
endothelium or increased vascular permeability
[13,20,35]. Epo expression tends to normalize shortly
after the onset of hypoxia or traumatic brain injury [36]
whereas EpoR can be induced for several days [37] which
may explain the observed differences in the incidence of
markers in the medulla of the malaria cases.
Correlation between the frequency of the markers on glia
and vascular-associated cells was strongest with markers
of cerebral hypoxia (CSF lactate) and systemic oxygen
availability (arterial oxygen saturation), peripheral para-
site load and sequestration. These findings are in agree-
ment with the literature showing that Epo and EpoR are
upregulated by hypoxia-inducible factors [15-18]. Epo
has been reported to inhibit cerebral oedema [20,38,39],
protect against vascular endothelial growth factor-
induced permeability of the BBB, and restore junctional
proteins [20]. There were no correlations between the fre-
quency of Epo, EpoR or CD131 labelling and fibrinogen
leakage. This supports our findings of multifactorial
mechanisms leading to increased vascular permeability in
severe malaria (Medana et al., personal communication).
The homodimeric EpoR receptor had been considered the
sole receptor responsible for Epo functions. However, car-
bamylated Epo, a derivative of Epo, does not bind the
homodimeric receptor yet has neuroprotective actions,
facilitates clinical recovery in various animal models and
appears to require the formation of a heteromeric receptor
consisting of EpoR and CD131 [28,40]. Although no stud-
ies have directly shown a role for CD131 in binding Epo
to the surface of any cell (reviewed in [41]), CD131 has
been shown to physically and/or functionally associate
with EpoR and coexpression of these receptors have been
observed using immunohistochemistry in tissue sections
from neurological disease models in animals [28,42,43].
It has even been suggested by some authors that a shift in
abundance of hetero- to homodimeric receptors may
divert Epo away from triggering potentially neuroprotec-
tive signals [3]. In this study there was a greater incidence
of EpoR in neurons in non-CM cases compared with CM
cases. However, there was a greater relative abundance of
CD131 to EpoR in CM cases compared with non-CM
cases. Taking all severe malaria cases together, the greatest
concordance of EpoR and CD131 occurred with neurons
(60% of cases). Although the relative contribution of neu-
roprotective Epo signalling in severe malaria is still not
clear, there is no evidence to suggest that cerebral compli-
cations are due to a lack of CD131 availability and poten-
tial heteromeric receptor formation in neurons of the
medulla. The incidence of EpoR and CD131 were discord-
ant in glia and vessels with heterogeneous staining in the
Table 4: Summary of neuropathological features in the brainstem of fatal severe malaria cases
Neuropathological feature
Haemorrhages
(% severe cases, n = 20)
Astrogliosis
(% severe cases, n = 19)
Swollen Axons
(% severe cases, n = 20)
Chromatolysis
(% severe cases, n = 20)
Grade NCM CM NCM CM NCM CM No. centres effected* NCM CM
0 40 20 15.8 26.3 20 10 1 25 10
1 0 10 36.8 15.8 15 10 2 10 10
2 0 15 0 5.3 15 30 3 15 25
31 0 5 0 0 0 0 4 0 5
* All cases had at least 1 centre with chromatolytic neurons. Brainstem centres included: oculomotor, motor Vth, VIIth, vestibular, reticular 
formation and raphe, lateral cuneate, deep pontine and Xth [25].Malaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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former and a predominance of EpoR in the latter. The way
in which Epo exerts neuroprotective signalling in different
cell types within the brain remains to be clarified.
Neurological complications reflect neuronal dysfunction.
Previous studies in this group with severe malaria have
shown no evidence for irreversible neuronal injury. How-
ever, there are neuronal stress responses, neuronal chro-
matolysis and axonal injury [25,26,31]. Chromatolysis
was observed in at least one brainstem centre in all of the
severe malaria patients analysed (n = 20, [25]), but endog-
enous Epo and receptor levels in the medulla did not
reflect the extent of neuronal chromatolysis in the brain-
stem.
It has been shown previously that axonal injury was quan-
titatively greater in CM cases compared with severe
malaria cases without neurological complications which
may represent a final common pathway leading to neuro-
logical dysfunction in CM [26,44]. Swollen axons are
commonly observed in these brainstem cases (Table 4). In
the current study, Epo receptors were rarely observed on
axons and Epo positive glia were not distributed around
axonal fibre tracts. Two studies of traumatic brain injury
(TBI) in mouse models have investigated the relationship
between axonal injury and endogenous/supplemented
Epo. In the first there was no significant difference
between the amount of axonal injury in EpoR null mice
(with endothelial EpoR restored) and wild type mice [37].
In the other model of TBI, mice were treated with recom-
binant human Epo (rhEpo). Similar amounts of axonal
injury were observed in the treated and untreated groups
during the acute phase of the degenerative process but
axons were relatively better preserved in the treated group
at later time points [45]. In this model, there is considera-
ble neuronal damage and it could not be concluded
whether the protective effect of Epo on axons is an epiphe-
nomenon to the protection of neurons or a direct effect on
axons. More recently, the possibility that Epo may amplify
axonal injury in its early stages following TBI has been
highlighted. The proposed mechanism suggests that Epo
could increase axonal calcium levels as it has been shown
to activate neural voltage-gated calcium channels [46].
Axonal injury in severe malaria is likely to involve
increased levels of intracellular calcium reflected by
increased levels of the calcium-activated cysteine protease,
calpain [47].
Two mechanisms by which Epo is thought to provide
cytoprotection is by increasing levels of heat shock protein
70 (HSP70) and by inhibition of caspase 3 [48,49].
HSP70 acts by binding to denatured proteins to restore
their structure and function enabling the proper function-
ing of cells in a hostile environment. Caspase 3 is acti-
vated early in the apoptotic cascade, at a stage when
commitment to loss of cell viability is made and is
required for some hallmarks of apoptosis such as disman-
tling of the cell and the formation of apoptotic bodies
(reviewed in [31]). In a previous study of these markers in
brainstem sections a robust induction of heat shock pro-
tein 70 and minimal activated capsase 3 labelling of neu-
rons was observed in severe malaria cases. Activated
caspase 3 labelling of glia could not be distinguished from
non-specific agonal levels observed in control groups
[31]. Whether the regulation of HSP70 and caspase 3 is a
consequence of Epo signalling or secondary to other pre-
conditioning responses is unknown. However, it does
raise the question of whether additional exogenous Epo
would be of any benefit.
Cytoadherence of parasitized red blood cells to endothe-
lial cells (EC) is central to the pathogenesis of cerebral and
severe malaria [19,50]. Epo can contribute to neuropro-
tection through its actions on the endothelium such as EC
survival, progenitor mobilization and angiogenesis and
modulation of endothelial NO production (reviewed in
[27]). NO is a potent vasodilator that is generated in
endothelial cells from L-arginine by constitutively
expressed endothelial NO synthase (eNOS). In this study,
a greater incidence of EpoR was observed on cerebral ves-
sels under conditions that would benefit from enhanced
oxygen delivery. It can be envisaged that Epo induced
eNOS could be protective in the context of severe malaria
infection by preserving cerebral blood flow, facilitating
effective collateral microcirculation, and anti-inflamma-
tory effects. However, it has been recognized that severe
malaria patients have reduced NO bioavailability due to
hypoarginaemia and haemolysis [51]. Treatment of severe
malaria cases with exogeneous Epo may, therefore, only
have a limited effect on the vasculature in the absence of
the eNOS signalling pathway irrespective of the presence
of increased numbers of Epo receptors. In this study there
was no correlation between the expression of Epo receptor
components on vessels and markers of vascular injury
such as plasma protein leakage and haemorrhage. It
should also be considered that severe malaria patients
with endothelial dysfunction caused by decreased NO
bioavailability could be at a higher risk of adverse effects
of exogenous Epo treatment such as increased blood vis-
cosity, thrombosis and increased expression of the vaso-
constrictor endothelin-1 (reviewed in [52]).
Conclusion
The incidence of endogenous Epo in parenchymal brain
cells did not greatly differ between severe malaria and
non-neurological UK controls at the time of death. How-
ever, the incidence of Epo receptor component levels in
neurons in severe malaria was greater than controls, sug-
gesting increased receptivity to Epo. The relative contribu-
tion of Epo signalling through homodimeric orMalaria Journal 2009, 8:261 http://www.malariajournal.com/content/8/1/261
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heteromeric Epo receptors is still not clear although there
was no evidence to suggest that histological or neurologi-
cal complications of severe malaria are due to a lack of
CD131 availability and potential heteromeric receptor
formation in neurons. It has been hypothesized that
axonal injury may represent a final common pathway
leading to neurological dysfunction in CM. There was no
indication that axons would be directly receptive to Epo
treatment since axons rarely expressed Epo receptors. Cor-
relations were observed between the incidence of EpoR on
vessels and markers of oxygen availability and sequestra-
tion. However, there were no correlations between the
incidence of Epo or its receptors on vessels and haemor-
rhage or increased vascular permeability. Much of the evi-
dence used to suggest Epo as an adjuvant in severe malaria
is based on the mouse model of CM. Its mode of action in
this model is the prevention of neuronal apoptosis and
inflammatory responses, that are not characteristic fea-
tures of CM in adults from south-east Asia. Data from
other studies imply that pharmacological doses of Epo
may have some value in ameliorating cerebral infarcts in
large vessel territories, although these are infrequent in
adults with CM. However this neuropathological study of
endogeneous Epo and its receptors at the microvascular
level does not provide a specific justification for the use of
Epo as an adjuvant treatment in CM.
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